Literature DB >> 11443731

Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees.

N Ertekin-Taner1, N Graff-Radford, L H Younkin, C Eckman, J Adamson, D J Schaid, J Blangero, M Hutton, S G Younkin.   

Abstract

Plasma amyloid beta42 peptide (Abeta42) levels are significantly elevated in all genetic forms of early-onset Alzheimer's disease caused by familial Alzheimer's disease mutations or Down's syndrome. Moreover, recent studies have determined that both plasma Abeta42 and Abeta40 levels are significantly elevated in late-onset Alzheimer's disease (LOAD) patients, their cognitively normal first-degree relatives, and members of typical LOAD families when compared to appropriate controls. To determine the magnitude of the genetic component affecting plasma Abeta levels, we estimated the heritability of plasma Abeta42 and Abeta40 in 15 extended, multigenerational LOAD pedigrees, using a variance components method. Heritability estimates as high as 73 and 54% were found for plasma Abeta42 and Abeta40 levels, respectively. Inclusion of the ApoE epsilon4 dosage as a covariate was not found to have a significant effect on the heritability of these traits. These results suggest that genetic determinants other than ApoE account for a very substantial percentage of the phenotypic variance in plasma Abeta levels. The high heritability and the significant elevation of these traits in LOAD pedigrees suggest that at least some of the genetic determinants of plasma Abeta levels may lead to elevated Abeta and LOAD in these families. Thus, we suggest that plasma Abeta levels are quantitative traits that may be excellent surrogate markers for use in linkage analysis to identify loci that are important in typical LOAD. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11443731     DOI: 10.1002/gepi.1015

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  16 in total

1.  Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy.

Authors:  Wesley Farris; Sonja G Schütz; John R Cirrito; Ganesh M Shankar; Xiaoyan Sun; Ana George; Malcolm A Leissring; Dominic M Walsh; Wei Qiao Qiu; David M Holtzman; Dennis J Selkoe
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

2.  Linkage analysis for plasma amyloid beta levels in persons with hypertension implicates Aβ-40 levels to presenilin 2.

Authors:  Carla A Ibrahim-Verbaas; Irina V Zorkoltseva; Najaf Amin; Maaike Schuur; Antonia M W Coppus; Aaron Isaacs; Yurii S Aulchenko; Monique M B Breteler; M Arfan Ikram; Tatiana I Axenovich; Marcel M Verbeek; John C van Swieten; Ben A Oostra; Cornelia M van Duijn
Journal:  Hum Genet       Date:  2012-08-08       Impact factor: 4.132

Review 3.  Epigenomics of Alzheimer's disease.

Authors:  David A Bennett; Lei Yu; Jingyun Yang; Gyan P Srivastava; Cristin Aubin; Philip L De Jager
Journal:  Transl Res       Date:  2014-05-16       Impact factor: 7.012

4.  Fine mapping of the alpha-T catenin gene to a quantitative trait locus on chromosome 10 in late-onset Alzheimer's disease pedigrees.

Authors:  Nilüfer Ertekin-Taner; James Ronald; Hideaki Asahara; Linda Younkin; Maria Hella; Shushant Jain; Eugene Gnida; Samuel Younkin; Daniel Fadale; Yasumasa Ohyagi; Adam Singleton; Leah Scanlin; Mariza de Andrade; Ronald Petersen; Neill Graff-Radford; Michael Hutton; Steven Younkin
Journal:  Hum Mol Genet       Date:  2003-10-14       Impact factor: 6.150

Review 5.  Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease.

Authors:  Esther S Oh; Juan C Troncoso; Stina M Fangmark Tucker
Journal:  Neuromolecular Med       Date:  2008-06-10       Impact factor: 3.843

Review 6.  Alzheimer disease therapy: can the amyloid cascade be halted?

Authors:  Todd E Golde
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

7.  A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease.

Authors:  Weiming Xia; Ting Yang; Ganesh Shankar; Imelda M Smith; Yong Shen; Dominic M Walsh; Dennis J Selkoe
Journal:  Arch Neurol       Date:  2009-02

Review 8.  Biomarkers for cognitive impairment and dementia in elderly people.

Authors:  Joshua A Sonnen; Kathleen S Montine; Joseph F Quinn; Jeffrey A Kaye; John C S Breitner; Thomas J Montine
Journal:  Lancet Neurol       Date:  2008-08       Impact factor: 44.182

9.  A Twin Study of Sex Differences in Genetic Risk for All Dementia, Alzheimer's Disease (AD), and Non-AD Dementia.

Authors:  Christopher R Beam; Cody Kaneshiro; Jung Yun Jang; Chandra A Reynolds; Nancy L Pedersen; Margaret Gatz
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

10.  A genome-wide association meta-analysis of plasma Aβ peptides concentrations in the elderly.

Authors:  V Chouraki; R F A G De Bruijn; J Chapuis; J C Bis; C Reitz; S Schraen; C A Ibrahim-Verbaas; B Grenier-Boley; C Delay; R Rogers; F Demiautte; A Mounier; A L Fitzpatrick; C Berr; J-F Dartigues; A G Uitterlinden; A Hofman; M Breteler; J T Becker; M Lathrop; N Schupf; A Alpérovitch; R Mayeux; C M van Duijn; L Buée; P Amouyel; O L Lopez; M A Ikram; C Tzourio; J-C Lambert
Journal:  Mol Psychiatry       Date:  2014-02-18       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.